**CORRECTION**

# Correction to: Intraoperative indocyanine green fluorescence imaging in breast surgery

Friedrich Kühn[1] · Jens-Uwe Blohmer[1] · Maria Margarete Karsten[1]

**Correction to: Archives of Gynecology and Obstetrics**
**https://doi.org/10.1007/s00404-020-05582-7**

In the original article published, some of the superscript characters in Table 1 (column $p$ value with superscript references to the footnotes) were incorrectly inserted by the typesetters. The correct table is given below.

**Table 1** General patient data, medical history and surgery

| Characteristics | SPY ($n=36$) | Control ($n=32$) | $p$ value |
|---|---|---|---|
| Age (years) | | | 0.245[+] |
| Mean (SD) | 43.4 (10.7) | 46.5 (10.7) | |
| | | | 0.808* |
| <45 | 16 (44.4%) | 16 (50.0%) | |
| ≥45 | 20 (55.6%) | 16 (50.0%) | |
| BMI (kg/m$^2$) | | | 0.280[$] |
| Median (IQR) | 23.4 (21.3–26.1) | 22.1 (20.8–26.5) | |
| | | | 0.585* |
| <25 | 20 (64.5%) | 21 (72.4%) | |
| ≥25 | 11 (35.5%) | 8 (27.6%) | |
| *Missing* | *5* | *3* | |
| Pregnancies | | | 0.197[$] |
| None | 8 (22.2%) | 8 (25.8%) | |
| 1 | 12 (33.3%) | 11 (35.5%) | |
| 2 | 7 (19.4%) | 10 (32.3%) | |
| ≥3 | 9 (25.0%) | 2 (6.5%) | |
| *Missing* | - | *1* | |
| Genetic predisposition for breast cancer | | | 0.460[$] |
| None known | 22 (61.1%) | 17 (53.1%) | |
| BRCA-1/-2 | 13 (36.1%) | 15 (46.9%) | |

The original article can be found online at https://doi.org/10.1007/s00404-020-05582-7.

✉ Friedrich Kühn
   friedrich.kuehn@charite.de

1   Department of Gynecology, Charité – Universitätsmedizin
    Berlin, Charitéplatz 1, 10117 Berlin, Germany

**Table 1** (continued)

| Characteristics | SPY (*n*=36) | Control (*n*=32) | *p* value |
|---|---|---|---|
| CHEK2 | 1 (2.8%) | 0 (0.0%) | |
| Comorbidities | | | |
| Diabetes mellitus | 0 (0.0%) | 1 (3.1%) | 0.478* |
| *Missing* | *1* | *–* | |
| Arterial hypertension | 5 (14.3%) | 2 (6.3%) | 0.431* |
| *Missing* | *1* | *–* | |
| Smoker | 4 (11.1%) | 5 (16.1%) | 0.723* |
| *Missing* | *–* | *1* | |
| Former smoker | 8 (22.2%) | 3 (9.7%) | 0.202* |
| *Missing* | *–* | *1* | |
| Prior surgery[a] | | | 0.808* |
| N (%) | 13 (36.1%) | 12.5 (39.1%) | |
| Type of prior surgery[a] | | | 0.180§ |
| BCS | 6.5 (50.0%) | 8.5 (68.0%) | |
| Mastectomy | 5 (38.5%) | 1 (8.0%) | |
| Other | 1.5 (11.5%) | 3 (24.0%) | |
| Local cancer therapy[a] | | | |
| Surgery | 9.5 (73.1%) | 9.5 (76.0%) | 1.0* |
| Adjuvant radiation | 6 (46.2%) | 3 (24.0%) | 0.370* |
| Surgery indication | | | 0.610§ |
| Carcinoma | 23 (63.9%) | 24 (75.0%) | |
| Prevention | 10 (27.8%) | 6 (18.8%) | |
| Other | 3 (8.3%) | 2 (6.3%) | |
| Side of surgery | | | 1.0* |
| Unilateral | 22 (61.1%) | 20 (62.5%) | |
| Bilateral | 14 (38.9%) | 12 (37.5%) | |
| Type of surgery[a] | | | 0.275§ |
| NSM | 18.5 (51.4%) | 19 (59.4%) | |
| SSM | 10 (27.8%) | 4 (12.5%) | |
| SSM with NAC reconstruction | 2 (5.6%) | 5 (15.6%) | |
| Other | 5.5 (15.3%) | 4 (12.5%) | |
| Neoadjuvant cancer therapy | | | 0.244* |
| N (%) | 23 (63.9%) | 24 (75.0%) | |
| Chemotherapy | 8 (34.8%) | 13 (54.2%) | |
| None | 15 (65.2%) | 11 (45.8%) | |
| Duration of surgery (h) | | | 0.124+ |
| Mean (SD) | 2:43 (0:48) | 2:24 (0:52) | |
| Resection weight (g)[a] | | | 0.153§ |
| Median (IQR) | 260 (149.3–381.8) | 254.5 (173–449.3) | |
| | | | 0.692* |
| < 500 g | 33.5 (93.1%) | 25.5 (86.4%) | |
| ≥ 500 g | 2.5 (6.9%) | 4 (13.6%) | |
| *Missing* | *–* | *2.5* | |
| Implant insertion[a] | | | 0.197* |
| N (%) | 28.5 (79.2%) | 29.5 (92.2%) | |
| Implant shape[a] | | | 0.023* |
| Round | 0 (0.0%) | 5.5 (19.3%) | |
| Anatomic | 27.5 (100%) | 23 (80.7%) | |

**Table 1** (continued)

| Characteristics | SPY (n=36) | Control (n=32) | p value |
|---|---|---|---|
| *Missing* | *1* | *1* | |
| Implant position[a] | | | 0.070* |
|   Epimuscular | 11 (38.6%) | 18.5 (62.7%) | |
|   Submuscular | 17.5 (61.4%) | 11 (37.3%) | |
| Implant volume (ml)[a] | | | 0.398$ |
|   Median (IQR) | 331.3 (257.5–420) | 308.8 (185–448.1) | |
| Expander insertion[a] | | | 0.434* |
|   N (%) | 5 (13.9%) | 2 (6.3%) | |
| Expander shape[a] | | | – |
|   Round | 0 (0.0%) | 0 (0.0%) | |
|   Anatomic | 5 (100%) | 2 (100%) | |
| Expander position[a] | | | 1.0* |
|   Epimuscular | 2 (40.0%) | 1 (50.0%) | |
|   Submuscular | 3 (60.0%) | 1 (50.0%) | |
| Expander volume (ml)[a] | | | 0.833$ |
|   Median (IQR) | 50 (50–225) | 155 (–) | |
| Autologous reconstruction (TRAM)[a] | 2 (5.6%) | 0 (0.0%) | 0.494* |
| Mesh insertion[a] | 11 (30.6%) | 6 (18.8%) | 0.401* |
| ADM insertion[a] | 4 (11.1%) | 1 (3.1%) | 0.360* |
| Lymph node intervention[a] | | | 0.537$ |
|   N (%) | 18.5 (51.7%) | 16 (50.0%) | |
|   SNB | 15.5 (83.8%) | 13 (81.3%) | |
|   AS | 2 (10.8%) | 3 (18.8%) | |
|   AD | 1 (5.4%) | 0 (0.0%) | |
| Subset with reduced perfusion in ICG fluorescence angiography[a] | | | |
|   N (%) | 11.5 (31.9%) | – | |
| Resection of tissue with reduced perfusion[a] | | – | |
|   Yes | 4 (34.8%) | – | |
|   No | 7.5 (65.2%) | – | |

Numbers in italics are missing values

*BCS* Breast conserving surgery, *NSM* nipple sparing mastectomy, *SSM* skin-sparing mastectomy, *NAC* nipple areola complex, *SNB* sentinel lymph node biopsy, *AS* axillary sampling, *AD* axillary dissection, *ICG* indocyanine green, *ADM* acellular dermal matrix, *SD* standard deviation, *IQR* interquartile range

[a] In the calculation of breast specific parameters women who underwent bilateral surgery were only counted as half item for each breast which ensures that no information gets lost and that no patient is counted twice in any category

Test on normal distribution: Shapiro–Wilk test

[+] t-test for independent samples

[$] Mann–Whitney-*U* test

*Fisher's exact test

[§] Chi-square-test